7 replies to this topic

[ImmInst]

cell therapies

[ImmInst]

Athersys (ATHX) Reports Rapid Clinical Progress Second Quarter
BiotechStockTrader.com - 2 hours ago

By Justin Kuepper on Thursday, August 11th, 2011 Athersys Inc. (Nasdaq: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like ...

View the full article

[ImmInst]

Why Athersys (ATHX) is a Compelling Investment Opportunity
BiotechStockTrader.com - 2 hours ago

Athersys Inc. (NASDAQ: ATHX) is a company focused on regenerative medicine, similar to companies like Osiris Therapeutics Inc. (NASDAQ: OSIR), Mesoblast (ASX:MSB), and Cytori (NASDQ: CYTX) and ...

View the full article

[ImmInst]

Athersys (ATHX) CEO to Deliver Keynote Address at World Stem Cell Summit 2011
BiotechStockTrader.com - 1 hour ago

Athersys Inc. (Nasdaq: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast (MSB: ASX), Osiris (Nasdaq: OSIR) and ...

View the full article

[ImmInst]

Athersys (ATHX) Releases Positive Results From MultiStem® Clinical Trial For ...
SECFilings.com - Feb 1, 2012

Athersys Inc. (NASDAQ: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast (ASX: MSB), Verastem Inc. (NASDAQ: VSTM) and Osiris (NASDAQ: OSIR), announced grant funding awards of ...

View the full article

[ImmInst]

ASX healthcare companies rebound in 2012: Acrux, ResMed, Mesoblast
Proactive Investors Australia - 1 hour ago

Proactive Investors brings you the latest news on the "Small-Mid Caps" listed on the Australian Securities Exchange. While the broader Australian market may not be performing so well lately due to ongoing eurozone concerns and a tumbling of precious ...

View the full article

[ImmInst]

Athersys (ATHX) Reports Solid Progress in 2011
BiotechStockTrader.com - Apr 5, 2012

Athersys Inc. (Nasdaq: ATHX), a clinical stage biotechnology company focused on the development of its proprietary MultiStem® cell therapy product for the treatment of numerous diseases and conditions, similar to companies like Mesoblast (MSB: ASX) and ...

View the full article

[ImmInst]

Athersys (ATHX) Secures New GvHD Patent for MultiStem
BiotechStockTrader.com - Apr 4, 2012

Athersys Inc. (NASDAQ: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast (ASX: MSB), Verastem Inc. (NASDAQ: VSTM) and Osiris (NASDAQ: OSIR), recently announced that it was ...

View the full article